China SXT Pharmaceuticals enters at-the-market equity sales agreement for up to $100 million offering

China SXT Pharmaceuticals, Inc

China SXT Pharmaceuticals, Inc

SXTC

0.00
  • China SXT Pharmaceuticals set an at-the-market equity program for up to USD 100 million of Class A ordinary shares via Univest Securities.
  • Univest will use commercially reasonable efforts to place shares, with sales expected to occur on Nasdaq or other trading venues.
  • Univest will earn a 3% commission on gross proceeds, with an added USD 0.003 per share trading and exchange fee reimbursement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China SXT Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-063591), on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.